Could The Market Be Wrong About Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (SZSE:300760) Given Its Attractive Financial Prospects?

It is hard to get excited after looking at Shenzhen Mindray Bio-Medical Electronics' (SZSE:300760) recent performance, when its stock has declined 2.8% over the past month. But if you pay close atte

Simply Wall StJun 5 23:10 ET

Is Shenzhen Mindray Bio-Medical Electronics (SZSE:300760) A Risky Investment?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know wor

Simply Wall StMay 21 21:34 ET

Mindray Healthcare (300760.SZ) 2023 equity distribution: 15 yuan for every 10 shares. The share registration date is May 27

Mindray Healthcare (300760.SZ) issued an announcement. The company's 2023 equity distribution plan is: Based on the company's existing...

Zhitong FinanceMay 20 04:55 ET

Galaxy Securities: The pharmaceutical industry's revenue growth rate is slowing down in 2023, and the worst is expected to pass

The Zhitong Finance App learned that Galaxy Securities released a research report saying that judging from the pace of growth in the pharmaceutical industry, expectations for the whole year are low and moving high. 24Q1 is expected to be the lowest point for the whole year, and a recovery in the pharmaceutical industry's growth rate can be expected from 24Q2. Currently, more emphasis is placed on innovation and device export direction: 1) Pharmaceutical innovation industry upgrading; 2) Colon Pharmaceutical (002422.SZ), etc., a platform-based pharmaceutical company with excellent management; 3) domestic replacement of equipment and overseas exports of Mindray Healthcare (300760.SZ), etc.; 4) Third-party medical testing Jinyu Medicine (603882.SH), etc.; 5) upstream life science,

Zhitong FinanceMay 12 18:32 ET

Illustration丨Capital from North China bucked the trend and added positions to Huichuan Technology, Hengrui Pharmaceutical, and Mindray Healthcare

The net sale of A-shares today was 4,044 billion yuan, the second consecutive day of net sales. Among them, Ping An Bank, Guodian Nanrui, and Zhongji Xuchuang received net sales of 255 million yuan, 242 million yuan, and 204 million yuan respectively; Huichuan Technology, Hengrui Pharmaceutical, and Mindray Healthcare bucked the trend and received net purchases of 395 million yuan, 299 million yuan, and 221 million yuan respectively. According to statistics, the capital from North China has been increasing Kweichow Moutai for 3 consecutive days, for a total of 4.265 billion yuan.

Gelonghui FinanceMay 8 05:37 ET

Mindray Healthcare (300760.SZ): The company's products in the field of medical imaging include ultrasound diagnostic systems, digital X-ray imaging systems, and PACS

On May 7, Ge Longhui Medical (300760.SZ) said on the investor interactive platform that the company's products in the field of medical imaging include ultrasound diagnostic systems, digital X-ray imaging systems, and PACS. In the field of ultrasound diagnostic systems, we provide hospitals, clinics, imaging centers, etc. with a full range of ultrasound diagnostic systems covering ultra-high-end to low-end, as well as specialized solutions for gradually segmented applications in different clinical specialties such as radiology, obstetrics and gynecology, intervention, emergency, anesthesia, severe illness, and liver fiber. In the field of digital X-ray imaging, the company provides radiology departments, ICU, and emergency departments including mobile, double column, and suspended models

Gelonghui FinanceMay 7 04:13 ET